Document Detail

Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.
MedLine Citation:
PMID:  24395613     Owner:  NLM     Status:  Publisher    
Although tumor necrosis factor (TNF)-antagonists are highly effective agents for the treatment of inflammatory bowel diseases (IBD), up to 40 % of patients ultimately lose response. As a result of the limited availability of treatment options, empiric dose escalation or switching of TNF-antagonists have evolved as strategies to regain response. Recently, therapeutic drug monitoring (TDM) (measurement of serum drug and antidrug antibody concentrations) has emerged to facilitate informed decision-making in patients with secondary loss of response to a TNF-antagonist. The evidence supporting the use of TDM in clinical practice and future applications of this approach will be discussed.
Reena Khanna; Brian G Feagan
Related Documents :
21143643 - Suspect novel adverse drug reactions to trimethoprim-sulphonamide combinations in horse...
22940233 - Can we reduce the dosage of biologics in spondyloarthritis?
2061433 - Recent advances in pediatric infectious diseases and their impact on dermatology.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-1-7
Journal Detail:
Title:  Current treatment options in gastroenterology     Volume:  -     ISSN:  1092-8472     ISO Abbreviation:  Curr Treat Options Gastroenterol     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815941     Medline TA:  Curr Treat Options Gastroenterol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Repeated versus single measurement of plasma omega-3 fatty acids and risk of heart failure.
Next Document:  Advances in the Treatment of Achalasia.